HOMOHARRINGTONINE: A NASCENT PHYTOCHEMICAL FOR CANCER TREATMENT (A REVIEW)
Vishal Bhagwan Badgujar*, Mohammed Tahir Ansari, Mohd Syafiq Abdullah and Sangita Vishal Badgujar
ABSTRACT
Recently homoharringtonine (HHT) was approved in October 2012 by
FDA for the treatment of adult patients with chronic or accelerated
phase chronic myeloid leukemia. The time spend for this approval was
more than 40 years, one of the historical for any drug to be approved
by FDA. Looking towards potential of HHT, we aim to review its long
journey. This review involves sources, chemistry, semisynthetic
formulation, extraction, new methods of production, characterization,
mechanism, and clinical development of homoharringtonine (HHT).
The compiled data will be helpful for the researchers to focus on
different aspects of HHT and its analogues. The data may prove useful
for anticancer research and areas of research yet to be discovered.
Keywords: homoharringtonine, omacetaxine mepesuccinate, chronic myeloid leukemia, Cephalotaxus harringtonia.
[Download Article]
[Download Certifiate]